Abstract library

564 results for "Ki-67 proliferation index".
#2871 Increase of Ki-67 Index over Time and Influence on All-Cause Mortality in Patients with Neuroendocrine Neoplasms (NEN)
Introduction: Increase of Ki-67 index in NEN over time in relation to progression and a potential influence on prognosis is scarcely studied.
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Epidemiology/Natural history/Prognosis - Registries, nationwide and regional surveys
Presenting Author: MD, PhD Pernille Holmager
#3036 Can Ki-67 with 5.5% Be Better in Predicting Prognosis for Well Differentiated Pancreatic Neuroendocrine Tumors?
Introduction: Pancreatic neuroendocrine tumors (NETs) are rare malignancies, Ki-67 is a cell proliferation marker that has been shown to have some utility in predicting prognosis of neuroendocrine tumors. However, the ideal grading method for G1/G2 remains controversial.
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Pathology - grading, staging
Presenting Author: Prof. Huang-Ying Tan
Authors: Yuan B, Chen Y Y, Zhang P, Wang X, ...
#2791 NEN Skeletal Metastasis Performance and the Correlation with Cell Proliferation: 112 Cases of 68Ga-DOTA-TATE Results Analysis
Introduction: 68Ga-DOTA-TATE PET/CT plays an important role in neuroendocrine neoplasm(NEN)diagnosis and biological charecteristcs evaluation.Skeleton is the second common metastatic organ in NEN after liver and it affects the quality of patient’s life.
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Nuclear Medicine - Imaging and Therapy (PRRT)
Presenting Author: Jiangyuan Yu
Authors: Xie Q, Lu M, Li J, Li N, ...
#3026 IMP3 and Ki-67-Factors of Poor Clinical Outcome in Neuroendocrine Tumors of the Lung
Introduction: Insulin- like growth factor-II messenger RNA- binding protein- 3 (IMP3) is often detected in malignant neoplasm of different sites. Ki-67 proliferative index, although helpful in diagnosing neuroendocrine tumours of lung, has not been recognised as prognostic factor.
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Basic Science - Signaling pathways, receptors, biomarkers
Presenting Author: Aleksandra Bełz
#2922 Clinicopathological Characteristics of Borderline Pulmonary Neuroendocrine Neoplasms
Introduction: According to the WHO 2015 classification pulmonary neuroendocrine neoplasms (NENs) are subdivided in carcinoids and neuroendocrine carcinoma (small cell lung carcinoma and large cell neuroendocrine carcinoma (LCNEC)), based on the presence of necrosis and mitotic index (MI). However, in some NENs a discrepancy is observed between grade of differentiation and proliferation rate.
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Pathology - grading, staging
Presenting Author: MD Bregtje Hermans
#3011 Added Prognostic Value of Molecular Imaging Biomarkers over Proliferation Index in Typical Lung Carcinoid: An FDG PET and SSTR Imaging Study
Introduction: Typical lung carcinoids(TCs)are rare tumors with good,although heterogeneous,prognosis.
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Biomarkers
Presenting Author: MD Vittorio Briganti
#9 Case Management of Metastatic carcinoid of the Foregut,Midgut and Hindgut:the relevance of Ki-67 prognostication
Introduction: The predictive value of tumor grade in the prognosis of carcinoid is insufficient and somehow misleading. The grade and differentiation in carcinoid tumors must be seen in conjunction with the Ki-67 index. The Ki-67 protein is a cellular marker for proliferation, present during all active phases of the cell cycle (G1, S, G2 and mitosis) and absent from resting cells (G0). It is therefore an excellent marker to determine the growth fraction of a given cell population. The Ki-67 labelling index is often correlated with the clinical course of carcinoid.
Conference: 7th Annual ENETS Conference (2010)
Category: Basic
Presenting Author: Dr Marianne J Kohler
Authors: Szpak W M, Stapleton G, ...
#18 Long-acting release octreotide induce complete response in type 1 gastric carcinoid tumors
Introduction: Gastric endocrine tumors (GET) are increasingly recognized due to expanding indications of upper gastrointestinal endoscopy. Often silent and benign, GET may also be aggressive when sporadic and may sometimes mimic the course of gastric adenocarcinoma. Current incidence of GETs is estimated at around 8% of digestive endocrine tumors. Yearly age-adjusted incidence is around 0.2 per population of 100,000. Gastric carcinoids (ECLomas) develop from gastric enterochromaffin-like cells (ECL cells) in response to chronically elevated gastrin. Type 1 tumors (ECLomas in the course of atrophic gastritis) may occur in conditions of achlorhydria secondary to auto-immune atrophic fundic gastritis. It occurs mostly in women and they are non-functioning tumors, typically found during upper GI endoscopy performed for dyspepsia. ECLomas present frequently as multiple polyps, usually < 1 cm in diameter in the gastric fundus. Type 1 tumors are almost exclusively benign lesions with little risk of deep invasion of the gastric parietal wall. The neoplastic ECL cells become progressively dedifferentiated with an increasing number of Ki-67 immunoreactive (IR) cell nuclei. In addition, there is a substantial decrease in argynophil and IR NE cells that can be visualized by conventional methods. ECLomas secondary to hypergastrinemia should be closely followed for signs of clinical and histopathological tumor progression. Such ECLomas deserve early, active, radical surgical treatment.
Traditionally, gastric carcinoid type 1 (GCA1s) are endoscopically or surgically removed, depending on the number, appearance and size of the tumors. Antrectomy, with surgical excision of the majority of the G cells, is thought to facilitate regression of these tumors by removing the source of excessive gastrin secretion; however, the long-term benefits of antrectomy still remain uncertain. Although proton pump inhibitors are effective in reducing hypergastrinemia-induced gastric acid hypersecretion in GCA2, they do not affect ECL-cell hyperplasia, and therefore their role in GCA1 is limited. Moreover, in selected cases, significant reduction of hypergastrinemia does not prevent development of ECL carcinoid, suggesting that, in addition to hypergastrinemia, other pathogenic or genetic factors may be involved. Treatment with somatostatin analogues (SSA) might impede ECL-cell hyperplasia by suppressing gastrin secretion and/or by a direct anti-proliferative effect on ECL cells. Treatment with SSAs in GCA1 leads to a substantial tumor load reduction, with a concomitant decrease of serum gastrin levels. Published data indicate an important anti-proliferative effect of SSA on ECL cells, providing clinical benefit and obviating, at least temporarily, the need for invasive therapies for GCA1. Morphometric studies demonstrated that, while antrectomy specifically decreased the volume of ECL cells versus the total volume of endocrine cells, octreotide reduces the overall endocrine cell volume. Although the number of treated patients is small, it has been suggested that SSA may exert important anti-proliferative effects either directly, by inhibiting ECL-cells proliferation, or indirectly through suppression of gastrin hypersecretion.
Conference: 7th Annual ENETS Conference (2010)
Category: Clinical
Presenting Author: MD Ricardo Caponero
#30 Diffuse Idiopathic Pulmonary Neuroendocrine Cell Hyperplasia
Introduction: Normal adult lungs contain scattered pulmonary neuroendocrine cells (PNEC). Reactive PNEC hyperplasia is commonly observed in persons who live at high altitude, in cigarette smokers, and in numerous lung diseases. Diffuse Idiopathic Pulmonary Neuroendocrine Cell Hyperplasia (DIPNECH) is a rare entity in which PNEC hyperplasia appears without predisposing conditions. According to the 1999 WHO lung tumor classification, DIPNECH is thought to be primarily a neuroendocrine proliferative process, which can be associated with carcinoid tumors and with a clinical picture of constrictive obliterative bronchiolitis. To date, available data regarding the treatment and the prognosis of this rare condition is limited.
Conference: 7th Annual ENETS Conference (2010)
Category: Clinical
Presenting Author: Dr. Simona Grozinsky-Glasberg
#33 Survival of Neuroendocrine Tumour Patients in Newcastle NHS Foundation Trust
Introduction: Neuroendocrine tumors (NETs) are rare neoplasms, with an incidence of 2-2.4 per 100,000, which derive from the neurones and epithelial cells of the diffuse neuroendocrine system. Neuropeptide-secreting NETs may present with overt clinical symptoms including abdominal pain, flushing and diarrhoea, whereas non-functioning NETs may be asymptomatic or present with obstructive symptoms. In Newcastle NHS Foundation Trust, NET patients are managed with a multi-disciplinary approach, according to UK and European NET guidelines.
Conference: 7th Annual ENETS Conference (2010)
Category: Clinical
Presenting Author: Dr Andy James
Authors: Hearn K, Teo L, Bernstone G, Johnson S, ...